pimavanserin and Non-alcoholic-Fatty-Liver-Disease

pimavanserin has been researched along with Non-alcoholic-Fatty-Liver-Disease* in 1 studies

Other Studies

1 other study(ies) available for pimavanserin and Non-alcoholic-Fatty-Liver-Disease

Article	Year
Design, Synthesis, and Biological Evaluation of New Peripheral 5HT Journal of medicinal chemistry, 2020, 04-23, Volume: 63, Issue:8 Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent worldwide, causing serious liver complications, including nonalcoholic steatohepatitis. Recent findings suggest that peripheral serotonin (5-hydroxytryptamine, 5HT) regulates energy homeostasis, including hepatic lipid metabolism. More specifically, liver-specific 5HT Topics: Animals; Diet, High-Fat; Drug Design; Drug Evaluation, Preclinical; HEK293 Cells; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Microsomes, Liver; Non-alcoholic Fatty Liver Disease; Rats, Sprague-Dawley; Serotonin 5-HT2 Receptor Antagonists	2020

Article

Year

Design, Synthesis, and Biological Evaluation of New Peripheral 5HT

Journal of medicinal chemistry, 2020, 04-23, Volume: 63, Issue:8

Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent worldwide, causing serious liver complications, including nonalcoholic steatohepatitis. Recent findings suggest that peripheral serotonin (5-hydroxytryptamine, 5HT) regulates energy homeostasis, including hepatic lipid metabolism. More specifically, liver-specific 5HT

Topics: Animals; Diet, High-Fat; Drug Design; Drug Evaluation, Preclinical; HEK293 Cells; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Microsomes, Liver; Non-alcoholic Fatty Liver Disease; Rats, Sprague-Dawley; Serotonin 5-HT2 Receptor Antagonists

2020